Clinical Scorecard: CREST Study Examines 2-Year Glaucoma Surgery Outcomes
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: CREST Study Examines 2-Year Glaucoma Surgery Outcomes |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | 575 eyes that received biointerventional uveoscleral outflow enhancement (AlloFloUveo; Iantrek) in the CREST study |
| Care Setting | Outcomes presented at 2026 AAO Glaucoma Subspecialty Day |
Key Highlights
- The presenter reported a 15% adverse event rate after 2 years.
- At 2 years, only 65% of eyes that otherwise would have been considered for bleb-forming surgery remained free of such procedures.
- At 2 years, IOP was about 30% lower than baseline.
- At 2 years, patients were using one fewer medication than at baseline.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The report describes 575 treated eyes; further patient characteristics are not provided.
At 2 years, IOP was about 30% below baseline and medication use was down by one from baseline. The presenter reported that only 65% of eyes otherwise considered for bleb-forming surgery remained free of those procedures.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.